News for Sino Biopharmaceutical Limited (SBHMY)

Beijing Tide Pharmaceutical, a subsidiary of Sino Biopharmaceutical (SBHMY), initiates Phase II trials for TRD205, a first-in-class AT2R antagonist. TRD205

BEIJING, May 6, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP) to enter Phase II clinical development, TRD205 is positioned to overcome the limitations of existing opioid therapies and provide a safer, more effective solution for hundreds of millions of patients worldwide.

Akeso, Sino Biopharmaceutical treatment targets nasopharyngeal cancer

- Dual Success of Innovative Drugs and Generic Drugs- Revenue Recorded RMB28.87 Billion- Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Reco

Sino Biopharmaceutical Limited (SBHMY) declares $0.0653/share quarterly dividend, payable Oct. 18 for shareholders of record Sept. 12.

6 June 2024Worldwide Healthcare Trust PLC ...

At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of...

Sino Biopharm (1177.HK) Announces 2023 Annual Results

An In-depth Analysis of the Company's Dividend History, Yield, Growth, and Sustainability Sino Biopharmaceutical Ltd (SBHMY) has recently announced a dividend o

Enhancing Cancer Patients' Quality of Life: Cancer Chemotherapy-Associated Nausea and Vomiting Therapeutics Market Offers Innovative Solutions to Alleviate...

Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaled RMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded...

Current national security tensions could put F-star's acquisition by Sino Biopharmaceutical at significant risk. Here's what investors in FSTX stock need to know.

FSTX seems undervalued, even at the $7.12 takeover bid. CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. Read more here.

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX...

/PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and...

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | December 29, 2022

Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till årsstämma torsdagen den 12 maj...

/PRNewswire/ -- Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the...